Johnson & Johnson Announces Collaboration with HP Inc. Subsidiary to Create Personalized Health Care Solutions with 3D Printing Technologies
NEW BRUNSWICK, N.J., May 17, 2016 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced a collaboration between Johnson & Johnson Services, Inc. and a subsidiary of HP Inc. The collaboration is focused on using 3D printing technologies to create better health care outcomes at reduced costs. Working together, the companies plan to combine their scientific, clinical, material science and technological expertise, and deep insights to develop products and solutions which can be manufactured quickly and customized to the needs of an individual patient or consumer.
In the near-term, the collaboration will focus on personalization of instrumentation and software for patient-specific healthcare devices. It is anticipated that 3D printing technology will lead to innovation in areas such as orthopaedics, eye health and consumer products, among others.
“The intersection of technology and health care is spurring innovation that will have a profound impact on patients and consumers all over the world,” said Sandra Peterson, Group Worldwide Chairman, Johnson & Johnson. “Combined with advances in data mining and software, 3D printing could enable distributed manufacturing models and patient-specific products, therapies and solutions that deliver better outcomes, better economics and improved global accessibility. This collaboration with HP Inc. exemplifies our commitment to harnessing new technology to improve outcomes and reduce costs across the health continuum.”
“Advances in 3D printing technology have the potential to break historical paradigms of health care delivery in ways that are not feasible in traditional manufacturing processes,” said Stephen Nigro, president of HP’s 3D printing business. “Together with Johnson & Johnson we have the potential to create opportunities and innovations in health care to improve patients’ lives that neither company could develop alone.”
The collaboration announced today has already begun, with teams of experts from both organizations working together.
About Johnson & Johnson
Caring for the world, one person at a time, inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 127,500 employees at more than 250 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
Cautions Concerning Forward-Looking Statements
This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to a new collaboration and product development. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson Services Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: the potential that the expected benefits and opportunities related to the collaboration may not be realized or may take longer to realize than expected; challenges inherent in new product development, including the uncertainty of success and obtaining regulatory approvals; competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2016, including in Exhibit 99 thereto, and the company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov,www.jnj.com or on request from Johnson & Johnson. Neither Johnson & Johnson Services Inc. nor Johnson & Johnson undertake to update any forward-looking statement as a result of new information or future events or developments.
SOURCE Johnson & Johnson
